Type 2 diabetes
Conditions
Interventions
None listed
Sponsors
Department of Medicine II, Hokkaido University Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Postmenopausal women. Patients of type 2 diabetes whose HbA1c(NGSP)is less than 10%. Patients who fit criteria for medication in guideline for preservation and medication of osteoporosis 2011. Patients whose treatment for diabetes has not been changed for more than 4 weeks when they entry this study. Patients who agreed with written consent form, receiving enough information of this study.
Exclusion criteria
Exclusion criteria: Patients who don't agreed with written consent form. Patients who are expected to change hypoglycemic agents, especially pioglitazone and incretin-based therapies, during observation period. Patients who have been treated with Bisphosphonate, SERM or PTH within 6 months. Patients who are suited for contraindications of bisphosphonate and SERM. Patients who are inappropriate for this study by research director.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| changes of serum pentosidine levels after six months of treatment of osteoporosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| change sof serum bone markers levels , bone density of lumbus and femur neck, FRAX, HbA1c and the general blood test after six months of treatment of osteoporosis. | — |
Countries
Japan
Contacts
Public ContactHideaki, Miyoshi
Hokkaido University Hospital Department of Medicine II
Outcome results
None listed